Apolipoprotein A1 and B

Clinics in Laboratory Medicine

Volumn 26, Issue 4, 2006, Pages 733-750

  Sniderman, Allan D ^a,b   Marcovina, Santica M ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL INTAKE; CLINICAL PRACTICE; DRUG DETERMINATION; EVIDENCE BASED PRACTICE; FAMILIAL HYPERLIPEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; LIPID ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIAS; RISK ASSESSMENT;

EID: 33750825308     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.07.007     Document Type: Review

References (94)

1. Levenson J.W., Skerrett P.J., and Gaziano J.M. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol 5 (2002) 188-199
2. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
3. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997) 3542-3556
4. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
5. Chapman M.J., Laplaud P.M., Luc G., et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 29 (1988) 442-458
6. Teng B., Thompson G.R., Sniderman A.D., et al. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinaemia, normolipidaemia and familial hypercholesterolaemia. Proc Natl Acad Sci USA 80 (1983) 6662-6666
7. Sniderman A.D., Vu H., and Cianflone K. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 89 (1991) 109-116
8. Durrington P.N., Bolton C.N., and Hartog H. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 82 (1978) 151-160
9. Stampfer M.J., Sacks F.M., Salvini S., et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
10. Buring J.E., O'Connor G.T., Goldhaber S.Z., et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 85 (1992) 22-29
11. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
12. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1 and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
13. Lamarche B., Moorjani S., Lupien P.J., et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Québec Cardiovascular Study. Circulation 94 (1996) 273-278
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285 (2001) 2486-2497
15. Marcovina S.M., Albers J.J., Dati F., et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 37 (1991) 1676-1682
16. Albers J.J., Marcovina S.M., and Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 38 (1992) 658-662
17. Marcovina S.M., Albers J.J., Henderson L.O., et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39 (1993) 773-781
18. Marcovina S.M., Albers J.J., Kennedy H., et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 (1994) 586-592
19. Bachorik P.S., Lovejoy K.L., Carroll M.D., et al. Apolipoprotein B and A1 distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 43 (1997) 2364-2378
20. Contois J.H., McNamara J.R., Lammi-Keefe C.J., et al. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 42 (1996) 515-523
21. Contois J.H., McNamara J.R., Lammi-Keef C.J., et al. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 42 (1996) 507-514
22. Jungner I., Marcovina S.M., Walldius G., et al. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 44 (1998) 1641-1649
23. Leino A., Impivaara O., Kaitsaari M., et al. Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Clin Chem 41 (1995) 1633-1636
24. Graziani M.S., Zanolla L., Righetti G., et al. Plasma apolipoproteins A-1 and B in survivors of myocardial infarction and in a control group. Clin Chem 44 (1998) 134-140
25. Rader D.J., Hoeg J.M., and Brewer H.B. Quantitation of plasma apolipoprotein in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120 (1994) 1012-1025
26. Salonen J.T., Salonen R., Penttila I., et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 56 (1985) 226-231
27. Wald N.J., Law M., Watt H.C., et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 343 (1994) 75-79
28. Sigurdsson G., Baldursdottir A., Sigvaldason H.A.U., et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 69 (1992) 1251-1254
29. St-Pierre A., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
30. Walldius G., Jungner I., Aastveit A.H., et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between the plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42 (2004) 1355-1363
31. Talmud P.J., Hawe E., Miller G.J., et al. Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
32. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
33. Corsetti J.P., Zareba W., Moss A.J., et al. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 177 (2004) 367-373
34. Shai I., Rimm E.B., Hankinson S.E., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 110 (2004) 2824-2830
35. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 (2004) 1991-1997
36. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
37. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998) 1453-1460
38. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
39. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
40. Sniderman A.D., St-Pierre A., Cantin B., et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91 (2003) 1173-1177
41. Veniant M.M., Withycombe S., and Young S.G. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arterioscler Thromb Vasc Biol 21 (2001) 1567-1570
42. Millar J.S., and Packard C.J. Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol 9 (1998) 197-202
43. Keulen E.T.P., Kruijshoop M., Schaper N.C., et al. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 22 (2002) 283-288
44. Simon A., Chironi G., Gariepy J., et al. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179 (2005) 339-344
45. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 361 (2003) 777-780
46. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
47. Bruno G., Merletti F., Biggeri A., et al. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato Study. Diabetologia 49 (2006) 937-944
48. Wagner A.M., Perez A., Zapico E., et al. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 26 (2003) 2048-2051
49. Williams K., Sniderman A.D., Sattar N., et al. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108 (2003) 2312-2316
50. Garvey W.T., Kwon S., Zheng D., et al. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
51. Goff D.C., D'Agostino Jr. R.B., Haffner S.M., et al. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 54 (2005) 264-270
52. Sattar N., Williams K., Sniderman A.D., et al. Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation 110 (2004) 2687-2693
53. Crouse J.R., Parks J.S., and Schey H.M. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 26 (1985) 566-574
54. Coresh J., Kwiterovich P.O., Smith H.H., et al. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34 (1993) 1687-1697
55. Campos H., Genest J.J., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb Vasc Biol 12 (1992) 187-195
56. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
57. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
58. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
59. Mykkanen L., Kuusisto J., Haffner S.M., et al. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 19 (1999) 2742-2748
60. Kamigaki A.S., Siscovick D., Schwartz S.M., et al. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol 153 (2001) 939-945
61. Austin M.A., Rodriguez B.L., McKnight S.G., et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 86 (2000) 412-416
62. Lamarche B., St-Pierre A.C., Ruel I.L., et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardio 17 (2001) 859-865
63. Krauss R.M., Lindgren F.T., Williams P.T., et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2 (1987) 62-66
64. Miller B.D., Alderman E.L., Haskell W.L., et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project. Circulation 94 (1996) 2146-2153
65. Watts G.F., Mandalia S., Brunt J.N., et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 42 (1993) 1461-1467
66. Zambon A., Hokanson J.E., Brown B.G., et al. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99 (1999) 1959-1964
67. Sniderman A.D., Wolfson C., Teng B., et al. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 97 (1982) 833-839
68. Griffin B.A., Minihane A.M., Furlonger N., et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci (Colch) 97 (1999) 269-276
69. Brunzell J.D., Schrott H.G., Motulsky A.G., et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25 (1976) 313-320
70. Durrington P.N., Hunt L., Ishola M., et al. Serum apolipoproteins AI and B and lipoprotein in middle-aged men with and without previous myocardial infarction. Br Heart J 56 (1986) 206-212
71. Barbir M., Wile D., Trayner I., et al. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 60 (1988) 397-403
72. Kukita H., Hamada M., Hiwada K., et al. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis 55 (1985) 143-149
73. Lamarche B., Despres J.P., Moorjani S., et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 75 (1995) 1189-1195
74. Jungner I., Sniderman A.D., Furberg C., et al. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?. Am J Cardiol (2006) In press
75. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1829-1831
76. Goldstein J.L., Schrott H.G., Hazzard W.R., et al. Hyperlipidaemia in coronary hearts disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidaemia. J Clin Invest 52 (1973) 1544-1568
77. Veerkamp M.J., de Graaf J., Bredie S.J., et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families. Results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 22 (2002) 274-282
78. Ayyobi A.F., McGladdery S.H., McNeely M.J., et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1-7
79. Brunzell J.D., Albers J.J., Chait A.I., et al. Plasma lipoproteins in familial combined hyperlipidaemia and monogenic hypertriglyceridaemia. J Lipid Res 24 (1983) 147-155
80. Chait A., Albers J.J., and Brunzell J.D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 10 (1980) 17-22
81. Janus E.D., Nicoll A., Turner P.R., et al. Kinetic bases of the primary hyperlipidaemias. Studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 10 (1980) 161-172
82. Kissebah A.H., Alfarsi S., and Adams P.W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 30 (1981) 856-868
83. del Rincon Jarero J.P., Aguilar-Salinas C.A., Guillen-Pineda L.E., et al. Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds. Metabolism 51 (2002) 218-224
84. Austin M.A., McKnight B., and Edwards K.L. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101 (2000) 2777-2782
85. Hopkins P.N., Heiss G., Ellison C., et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. Circulation 108 (2003) 1-5
86. Sniderman A.D., Castro Cabezas M., Ribalta J., et al. A proposal to redefine familial combined hyperlipidaemia-third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 32 (2002) 71-73
87. Roeters van Lennep J.E., Westerveld H.T., Roeters van Lennep H.W.O., et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20 (2000) 2408-2413
88. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
89. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 (2002) 22-29
90. Ballantyne C.M., Andrews T.C., Hsia J.A., et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
91. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 9A (2005) 36-43
92. Collins-Nakai R.L., and Dagenais G.R. The role of the cardiovascular specialist in the prevention of cardiovascular diseases-executive summary. Can J Cardiol 15 (1999) 7G-16G
93. Genest J., Frohlich J., Fodor G., et al. Working group on hypercholesterolemia and other dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 169 (2003) 921-924
94. Leiter L.A., Mahon J., Chye T., et al. Macrovascular complications, dyslipidemia and hypertension. Can J Diabetes 27 (2003) S58-S65